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Abstract Chronic glomerular and tubular nephrotoxicity is
reported in 20–50% and 20–25%, respectively, of children
and adolescents treated with ifosfamide and 60–80% and
10–30%, respectively, of those given cisplatin. Up to 20% of
children display evidence of chronic glomerular damage after
unilateral nephrectomy for a renal tumour. Overall, childhood
cancer survivors have a ninefold higher risk of developing
renal failure compared with their siblings. Such chronic neph-
rotoxicity may have multiple causes, including chemotherapy,
radiotherapy exposure to kidneys, renal surgery, supportive
care drugs and tumour-related factors. These cause a wide
range of chronic glomerular and tubular toxicities, often with
potentially severe clinical sequelae. Many risk factors for de-
veloping nephrotoxicity, mostly patient and treatment related,
have been described, but we remain unable to predict all epi-
sodes of renal damage. This implies that other factors may be
involved, such as genetic polymorphisms influencing drug
metabolism. Although our knowledge of the long-term out-
comes of chronic nephrotoxicity is increasing, there is still
much to learn, including how we can optimally predict or
achieve early detection of nephrotoxicity. Greater understand-
ing of the pathogenesis of nephrotoxicity is needed before its
occurrence can be prevented.
Keywords Nephrotoxicity . Glomerular toxicity . Renal
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Introduction
Paediatric and adult nephrologists and oncologists involved in
long-term follow-up of childhood cancer survivors (CCS) en-
counter many patients with chronic glomerular and/or renal
tubular impairment. Balancing the long-term risks and benefits
of potentially nephrotoxic treatments is tricky, and progress in
preventing nephrotoxicity remains frustratingly out of reach. In
addition, it remains difficult to achieve accurate early recogni-
tion, let alone prediction, of incipient significant renal dysfunc-
tion that would potentially allow treatment modification early
enough to avoid chronic nephrotoxicity. A report from the
Childhood Cancer Survivor Study of >10,000 CCS treated in
the 1970s and 1980s reported that 0.5% had developed renal
failure or were requiring dialysis by a mean age of 27 years
(18 years from initial cancer diagnosis), representing a ninefold
increased risk compared with their siblings [1]. Although mod-
ern treatment protocols have been designed with the intention
of reducing chronic renal toxicity, the greater use of potentially
nephrotoxic chemotherapy since the 1970s and the ever-
increasing intensity of treatment regimens for many diagnoses,
implies that chronic nephrotoxicity will probably be at least as
prevalent in contemporary CCS cohorts.
The causes of such chronic renal damage in CCS are var-
ied. Occasionally, malignant disease itself may cause chronic
renal impairment, for example, by damaging normal renal
tissue by tumour infiltration, or long-term sequelae of urinary
tract obstruction or tumour lysis syndrome. There are many
treatment-related causes for chronic renal damage in CCS,
including chemotherapy (most commonly cisplatin or
ifosfamide), radiotherapy, surgery, immunotherapy and sup-
portive treatment (aminoglycoside antibiotics, amphotericin).
The kidneys’ excretory function relies on high renal blood
flow across a large glomerular endothelial surface area follow-
ed by extremely active tubular reabsorption and secretion, but
* Roderick Skinner
Roderick.Skinner@ncl.ac.uk
1 Department of Paediatric and Adolescent Haematology/Oncology,
and Children’s Haemopoietic Stem Cell Transplant Unit, Great North
Children’s Hospital, Newcastle upon Tyne NE1 4LP, UK
Pediatr Nephrol
DOI 10.1007/s00467-017-3662-z
these normal physiological processes expose renal cells to
toxic substances that may accumulate or undergo further in-
tracellular metabolism. It is therefore not surprising that the
kidneys are highly vulnerable to damaging adverse effects
from a variety of drugs as they undergo renal excretion and
metabolism [2]. The reliance of kidney function on complex
vascular structures and metabolically active cells renders renal
tissue very sensitive to radiotherapy. Chronic radiation ne-
phropathy may present with proteinuria, hypertension and re-
duced glomerular filtration rate (GFR), which may be progres-
sive, and was observed in 46% of adults who received 20 Gy
radiotherapy exposing the left kidney during treatment for
peptic ulcer disease [3, 4]. The severity of chronic kidney
disease (CKD) appears to be related to dose and treatment
volume, and dose–volume constraints have been recommend-
ed based on an estimated risk for chronic nephrotoxicity of
<5% [3]. Renal haemodynamics may be significantly dis-
turbed by direct destruction or removal of large amounts of
renal tissue—as in renal tumours or infiltration—or surgery
for renal tumours leading to diminished glomerular filtration
surface area and hence reduced GFR, or hyperfiltration across
the remaining glomeruli, or a mixture of both. Glomerular
hyperfiltration is well documented as a long-term conse-
quence of nephrectomy [5], whilst case reports in CCS have
described proteinuria, hypertension and progressive CKD due
to focal glomerulosclerosis, most likely as a consequence of
hyperfiltration [6]. A recent single-centre study revealed that
of 35 adult-aged, long-term (≥5 years) survivors of childhood
nonsyndromic unilateral renal tumours treated by unilateral
nephrectomy, chemotherapy (in 31 survivors) and radiothera-
py (in 8), 23% had a mildly reduced GFR (60–89 ml/min/
1.73m2), 9% chronic albuminuria and 3% hypertension [7].
It is important to recognise that the consequences of nephro-
toxicity are not limited to the direct sequelae of renal impair-
ment. Significant glomerular dysfunction may limit further
chemotherapy options available to the patient during both
first-line and subsequent relapse treatment and may ultimately
have an adverse effect on the patient’s outcome by preventing
use of optimum chemotherapy agents and schedules.
This educational review summarises what we know and
what we are still learning about these important issues, with
particular emphasis on nephrotoxicity due to ifosfamide and
platinum agents (cisplatin and carboplatin), since these remain
the most frequently encountered drug-related causes of chron-
ic renal impairment in CCS. It also outlines clinical character-
istics, risk factors and management of ifosfamide and
platinum-induced nephrotoxicity and describes emerging in-
formation on long-term outcomes. It then reflects on our still
incomplete knowledge of why nephrotoxicity occurs and how
we can best detect it at an early and potentially modifiable
stage, or even ideally prevent it happening at all. Finally, it
highlights the lack of knowledge about the potential for chron-
ic nephrotoxicity in patients treated with the emerging
generation of anticancer drugs and the very-long-term (i.e.
≥20 years) outcome of chronic renal damage in CCS.
What do we already know?
Clinical features of chronic nephrotoxicity
Ifosfamide
Ifosfamide may cause both acute and chronic glomerular and
tubular damage. Acute glomerular toxicity manifesting as
acute kidney injury (AKI) is uncommon in children but well
recognised in adults [8]. Renal function may not recover fully,
leading to CKD, or the latter may occur even in the absence of
a previous episode of AKI [9, 10]. Stages 2 and 3 CKD have
been reported in 20–50% of children and adolescents after
completion of ifosfamide treatment [11, 12]. Acute proximal
tubular toxicity occurs in 20–25% of children given
ifosfamide, typically leading to hypophosphataemia due to
phosphaturia [12]. If prolonged, hypophosphataemic rickets
(HR) [13] may ensue, or osteomalacia in adults [14]. More
detailed evaluation usually reveals renal glycosuria (in the
absence of hyperglycaemia) and aminoaciduria, whilst proxi-
mal renal tubular acidosis (RTA) may be identified and—in
severe cases—a generalised proximal tubular reabsorptive im-
pairment (Fanconi syndrome) [12, 13]. Although reported less
commonly, significant distal nephron impairment may lead to
nephrogenic diabetes insipidus, resulting in severe polyuria,
and distal RTA [13]. These acute toxicities may complicate
delivery of anticancer treatment and often persist for years
after treatment completion, resulting in long-term electrolyte
and mineral supplementation orally. However, more recent
long-term follow-up studies have suggested that tubular tox-
icity improves over a period of several years [15], although
similar recovery does not appear to occur in glomerular func-
tion. Significant chronic ifosfamide nephrotoxicity appears to
be common in adults, with 45% of 217 1-year survivors and
53% of 154 5-year survivors with CKD stage ≥3 in a large
cohort study [16]. Additional features of chronic nephrotoxi-
city include hypertension (although this appears to be uncom-
mon) and growth impairment due to HR [13, 17].
Platinum agents
Cisplatin Likewise, cisplatin may also cause both acute and
chronic glomerular and tubular toxicity. Compared with
ifosfamide, there are more reports, both in case series and
individual case reports, of AKI and subsequent CKD due to
cisplatin [18–20]. The frequency of CKD with reduced GFR
(stage ≥2) is reported to be 60–80% in children treated with
cisplatin [12, 13]. In contrast to that associated with
ifosfamide, cisplatin-induced tubular damage leads to
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magnesuria and hence chronic hypomagnesaemia, which is
reported in 10–30% of children treated with cisplatin [18,
19, 21]. Hypocalcaemia may occur less commonly and usual-
ly appears to be secondary to hypomagnesaemia [22]. More
subtle distal nephron damage is described, resulting in the
association of hypocalciuria and hypokalaemic metabolic al-
kalosis, as well as polyuria, the consequences of which are
seldom clinically significant [23]. Thrombotic microangiopa-
thy (TMA), sometimes described as haemolyic uraemic syn-
drome (HUS) in older literature, may cause AKI after cisplatin
treatment [24]—although it is more commonly seen in
adults—following treatment with mitomycin, gemcitabine or
targeted anticancer agents [25]. Chronic glomerular damage is
also common in adults, with a large cohort study reporting
stage 3 CKD in 29% of 533 1-year survivors and 33% of
3975-year survivors treated with cisplatin [26]. Hypertension
is also well described and may be due to vascular or renal
toxicity or both [27].
Carboplatin Carboplatin nephrotoxicity is similar in nature in
terms of causing glomerular impairment and hypomagnesaemia
but less common (especially for glomerular toxicity) and usually
much less severe than cisplatin-induced renal toxicity [21, 28].
Risk factors
Knowledge of risk factors for the development of treatment-
associated acute and chronic nephrotoxicity in children with
cancer is clearly vital in the clinical care of individual patients.
It also facilitates the design of future treatment protocols by
improving understanding about the relative likelihood of effi-
cacy and risk of toxicity and allowing more informed use of
potentially harmful treatments. Agents in current use likely to
cause nephrotoxicity are also highly effective at treating can-
cer, so their continued use remains necessary to maximise the
chances of cure for as many children as possible. As for many
widely used contemporary cytotoxic treatments for childhood
malignancy, it remains important to learn how to use the
existing potentially toxic treatments more safely until we find
better alternatives [29].
In general, risk factors may be patient (e.g. age at treatment,
previous history of renal disease, toxicity) or treatment related.
Timing of assessment may also be a factor where the likeli-
hood and/or severity of toxicity is characterised by deteriora-
tion (e.g. in chronic radiation nephropathy [3, 4]) or improve-
ment (e.g. ifosfamide-induced tubular toxicity [15]).
Treatment-related factors differ according to the treatment in
question but may include drug (or radiation) dose (both indi-
vidual and cumulative doses), dose schedule and intensity (i.e.
howmuch over a specific period of time) and pharmacological
parameters (e.g. a drug’s pharmacokinetic profile). However,
there is increasing recognition that these traditional risk factors
fail to explain all episodes of renal toxicity. Indeed, although
poorly understood in the context of nephrotoxicity, there is
emerging interest in the study of pharmacogenetics whereby
patient and treatment factors may interact in some individual
patients with increased vulnerability due to particular genetic
polymorphisms affecting, for example, drug metabolism or
renal tubular excretion, thus increasing the risk of toxicity
even after low treatment doses [30].
Ifosfamide
Treatment-related risk factors for ifosfamide nephrotoxicity
are well established and include a high cumulative ifosfamide
dose [10, 12, 31], previous or concurrent treatment with cis-
platin and prior nephrectomy [32]. Young age at treatment
also appears to be relevant [10], although its importance as a
predictor of toxicity remains uncertain, with some studies
reporting no effect independent of cumulative ifosfamide
dose. Clinical experience suggests, and several studies appear
to show, an increased risk of nephrotoxicity in young children
[10, 31, 33, 34], although others have not confirmed this ob-
servation [12, 32]. Most published reports of severe toxicity
are in infants and young children, a population highly vulner-
able to proximal tubular toxicity and its consequences, such as
growth impairment [13]. Nevertheless, there remains uncer-
tainty about the role of confounding factors, such as cumula-
tive ifosfamide dose and additional cisplatin treatment.
Furthermore, some large medium-term studies do not show
an independent effect of young age [12, 32], whilst very-long-
term studies show either no [15] or only a weak effect (relative
risk 1.08) of older age at treatment [35].
Although poorly documented in published studies, the im-
portance of pre-existing renal impairment is widely
recognised in clinical practice and consistent with the known
adverse impact of prior nephrectomy [32]. In contrast to initial
hopes, there is no evidence that the ifosfamide administration
infusion duration (bolus, short or prolonged infusion), nor the
drug’s pharmacokinetic profile, influence long-term nephro-
toxicity [36]. Although currently known risk factors fail to
predict all episodes of chronic ifosfamide nephrotoxicity,
avoidance of higher cumulative ifosfamide doses may contrib-
ute to a reduction in their frequency and severity. However,
although lower doses are associated with less acute tubular
toxicity [37], no randomised clinical trial or comparative lon-
gitudinal epidemiological data is available to confirm that
long-term toxicity is reduced.
A cross-sectional study of 148 patients treated with a me-
dian (range) of 62 (6–165) g/m2 ifosfamide at 8.1 (0.1–25)
years and studied 6 (1–47) months after completion of treat-
ment demonstrated highly significant relationships between
higher ifosfamide cumulative dose and greater chronic glo-
merular (evaluated by radioisotope clearance GFR), proximal
tubular [(serum phosphate, serum bicarbonate, renal tubular
threshold for phosphate (TmP/GFR) and overal l
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nephrotoxicity (total nephrotoxicity score; a composite of
measures of glomerular, proximal and distal nephron func-
tion) [12]. However, closer inspection of data from this study
illustrates the difficulty of predicting risk accurately, since
there was considerable overlap between doses received by
patients with and without abnormal renal function (Fig. 1).
Using the total nephrotoxicity score to quantify the overall
severity of nephrotoxicity, an increase in cumulative
ifosfamide dose of 50 g/m2 increased the risk of moderate/
severe toxicity nearly sevenfold. Although 7% of patients re-
ceiving ≤57 g/m2 ifosfamide developed moderate nephrotox-
icity, severe toxicity was only observed in those who had
received ≥84 g/m2 (Fig. 2). Multivariate analysis failed to
reveal any significant independent effect of age at treatment,
ifosfamide infusion schedule, or exposure to other potentially
nephrotoxic agents (e.g. aminoglycosides) on nephrotoxicity.
It is important to acknowledge that risk factor analyses are
necessarily limited by patient populations being studied and
particularly the treatment they received. For example, in con-
trast to the previous study in which only three children re-
ceived cisplatin and none underwent renal surgery, another
cross-sectional study of 120 children and young adults includ-
ed ten who underwent unilateral nephrectomy and 51 who
also received cisplatin, The authors found that nephrectomised
children had an 11-fold increased risk of developing Fanconi
syndrome and those exposed to cisplatin a sixfold higher risk
of developing phosphaturia and aminoaciduria [32]. The study
also failed to find any influence of age at initial diagnosis on
subsequent nephrotoxicity. Although pharmacological factors
have been postulated as predictors of ifosfamide nephrotoxi-
city, no simple relationship has been identified between mea-
sure of ifosfamide’s pharmacokinetic or metabolic profile and
either acute or chronic nephrotoxicity [36].
In summary, given our current state of knowledge,
established patient- and treatment-related risk factors are un-
able to reliably predict all cases of significant ifosfamide
nephrotoxicity.
Platinum
There is little information about risk factors for cisplatin neph-
rotoxicity in children, but high total dose and dose rate, patient
age, concurrent treatment with other potential nephrotoxins
and interindividual differences in cisplatin pharmacokinetics
appear to be relevant. Marked glomerular (GFR) and tubular
(hypomagnesaemia) toxicity was reported after a high dose
rate of cisplatin (i.e. at least 40 mg/m2/day) in adults [38,
39], whilst higher dose rates (>40mg/m2/day) were associated
with greater glomerular and tubular toxicity than a lower dose
rate (40 mg/m2/day) in children [19]. However, the influence
of total dose is uncertain, with some studies in adults and
children describing a relationship between cumulative dose
and nephrotoxicity [23, 40] and others finding no such rela-
tionship [18, 19]. Earlier studies found no relationship be-
tween age and cisplatin nephrotoxicity in children [18, 19],
but recent evidence suggests that very-long-term glomerular
and tubular toxicity may be more common in children treated
at an older age [41]. Although there is extensive clinical ex-
perience and some published evidence that treatment with
other potential nephrotoxins, including ifosfamide, metho-
trexate and aminoglycosides, may exacerbate nephrotoxicity
[32], and that interindividual variability in cisplatin pharma-
cokinetics may be important [42], there is no evidence that the
risk of nephrotoxicity in clinical practice can be reduced by
pharmacokinetically guided dose modification.
In contrast to cisplatin, frequency and severity of
carboplatin-induced chronic hypomagnesaemia in children
appears to be related to cumulative dose and older age at
treatment initiation, and long-term glomerular impairment is
also more common in older children [28, 41]. Since the main
route of carboplatin clearance is via glomerular filtration, it is
unsurprising that other potentially nephrotoxic chemothera-
peutic agents (e.g. cisplatin, ifosfamide, melphalan) [43–46]
and pre-existing renal dysfunction [47] may increase
carboplatin-induced renal damage.
Relevance of risk factors in predicting nephrotoxicity
Treatment-related (especially dose characteristics) and, to a
lesser extent, patient-related (e.g. age at treatment) risk factors
may predict an increased risk of nephrotoxicity, but they do
not predict all episodes of significant nephrotoxicity.
Fig. 1 Relationship between cumulative dose of ifosfamide received and
renal tubular threshold for phosphate/glomerular filtration rate (TmP/
GFR) in 103 children and adolescents at a median of 6 months after
ifosfamide treatment. Patients receiving ifosfamide as a short (3-h) infu-
sion (+) or as a continuous infusion (■) are distinguished. Multiple
regression analysis showed a highly significant inverse relationship
between cumulative ifosfamide dose and TmP/GFR), a measure of phos-
phaturia severity. Severe proximal tubular toxicity (defined by
hypophosphataemic rickets or myopathy, or by TmP/GFR ≤0.60 mmol/
l at <12months age or ≤0.50mmol/l at ≥1 year age) was only observed in
patients treated with higher doses of >80 g/m2. With permission [12]
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Conversely, not all patients with risk factors develop impor-
tant nephrotoxicity. Therefore, although future treatment pro-
tocols may incorporate appropriate dose ceilings for potential-
ly nephrotoxic agents in an attempt to limit chronic renal dam-
age (assuming there is sufficient evidence that efficacy is still
maintained despite the lower doses), this strategy may still fail
to protect all patients from nephrotoxicity. Careful consider-
ation of other important risk factors is necessary, both for
protocol design (e.g. caution with the use of ifosfamide in
younger children, avoidance of higher cisplatin dose rates)
and in individual patients (e.g. dose reduction or even avoid-
ance of nephrotoxic agents in patients with pre-existing renal
dysfunction). However, it is always important to balance the
risks posed by the underlying cancer (with the potentially fatal
consequences of inadequate treatment) against those of the
possibility of life-changing chronic toxicity.
Management of chronic ifosfamide-
and platinum-induced nephrotoxicity
Ideally, nephrotoxicity should be minimised before chronic
damage has occurred by stopping or modifying further treat-
ment with the causative drug, but the effectiveness of this
strategy is limited by the delayed onset of clinically significant
renal damage in many cases, particularly of ifosfamide neph-
rotoxicity [11]. Furthermore, clinicians must balance the risk
(for renal function) of continuing potentially damaging treat-
ment versus the potential risk (for the likelihood of cure) of
stopping it, often in the absence of proven data to guide them.
Consequently, management of chronic nephrotoxicity is often
supportive, aiming to prevent or ameliorate manifestations of
established severe toxicity. Ifosfamide-induced tubular neph-
rotoxicity may necessitate prolonged supplementation with
high doses of phosphate or bicarbonate to prevent HR and
manifestations of RTA in growing children. Proximal RTA is
difficult to correct fully, since increasing doses of bicarbonate
exceed the tubular bicarbonate reabsorption threshold and are
therefore simply excreted. Although 1α-hydroxy vitamin D3
may be beneficial in some children, this treatment carries a
potential risk of metastatic calcification and nephrocalcinosis,
especially in normocalcaemic patients. Magnesium supple-
mentation may be required to prevent manifestations of severe
hypomagnesaemia—such as tetany, convulsions or cardiac
arrhythmias—in platinum-induced nephrotoxicity [48, 49].
Supplementation should be monitored carefully to ensure bio-
chemical abnormalities are being corrected adequately and
safely.
For the small but important subgroup of children with CKD
due to severe drug-related glomerular toxicity or following
extensive tumour surgery, standard renal monitoring and man-
agement should be instituted. Serial trends in serum creatinine
concentration should be monitored and GFR measured when
clinically indicated, although the limitations of calculated
GFR based on single creatinine measurements in this patient
group should be recognised [50]. Blood pressure and urine
protein should be monitored regularly, since the pace of pro-
gressive glomerular impairment may be delayed by meticu-
lous control of hypertension and introduction of an
angiotensin-converting enzyme inhibitor (ACEi) or angioten-
sin II blocker in survivors with significant proteinuria [51]. In
end-stage renal disease (ESRD), standard renal replacement
treatment strategies (dialysis or transplantation) are usually
Fig. 2 Distribution of no, mild, moderate and severe ifosfamide
nephrotoxicity amongst 76 children and adolescents, assessed by
calculating total nephrotoxicity score. Patients are divided into five
groups according to total dose of ifosfamide received. Total
nephrotoxicity score was derived from measurement and scoring of
glomerular filtration rate (GFR), renal tubular threshold for phosphate
(TmP)/GFR, serum bicarbonate concentration and early-morning urine
osmolality. These measures give an overall evaluation of clinically im-
portant glomerular, proximal and distal nephron nephrotoxicity due to
ifosfamide, reflecting those aspects of toxicity with the potential to cause
morbidity or require chronic treatment. Each measure was scored on a 0–
4 scale, with 0 representing no, 1 mild, 2–3moderate and 4 severe toxicity
within each individual aspect of renal damage. The individual scores are
summated to give a nephrotoxicity score potentially ranging from 0 to 16.
No patient receiving <84 g/m2 experienced severe and 20% moderate
nephrotoxicity; of those receiving >119 g/m2, 33% experienced severe
and 40% moderate nephrotoxicity. With permission [12]
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appropriate in CCS, but the feasibility of some may be limited
by previous treatments and interventions (e.g. extensive ab-
dominal surgery, difficulties in vascular access after previous
central lines).
Long-term outcomes
In recent years, the frequency, nature and severity of very-
long-term nephrotoxicity in CCS treated at least 5 years pre-
viously has been investigated, providing further evidence
about the predictors for such late renal outcomes. GFR was
calculated with the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula in a cohort of 1122 5-year
CCS seen in a single long-term follow-up clinic, with longi-
tudinal data (median of 6 GFR measurements) available in
920 survivors.Median follow-up fromdiagnosis was 21 years,
and all survivors were at least 18 years old at study [52].
Glomerular dysfunction was defined as a GFR <90 ml/min/
1.73m2 and potentially nephrotoxic treatment as ifosfamide,
cisplatin, carboplatin, high-dose methotrexate, high-dose cy-
clophosphamide, radiotherapy to the kidneys or nephrectomy.
In survivors previously given potentially nephrotoxic treat-
ment, compared with survivors who had not, GFR was lower
[mean 95.2; 95% confidence interval (CI) 92.2–97.9 vs 100.2;
98.1–102.3 ml/min/1.73m2; p < 0.001] and the likelihood of
glomerular dysfunction was higher [mean 26.4 (20.6–33.0) vs
6.6% (4.4–9.6); p < 0.001] up to 35 years posttreatment. GFR
continued to fall with time. The highest risks were observed
with larger cumulative doses of ifosfamide and cisplatin (es-
pecially >500 mg/m2) and with nephrectomy (especially in
survivors older at the time of nephrectomy) [52].
Another study from the same group documented the preva-
lence of renal dysfunction in 1442 CCS evaluated once each at
a median age of 19 years and median follow-up of 12.1 years
from initial diagnosis. They measured blood pressure, serum
magnesium, serum phosphate and urine albumin concentra-
tions and calculated GFR using the Schwartz (in children) or
CKD-EPI (in adults) formula [53]. Overall, 28.1% of survivors
had at least one abnormality, including hypertension in 14.8%,
albuminuria in 14.5%, reduced GFR (<90 ml/min/1.73m2) in
4.5%, hypomagnesaemia in 8.8% and hypophosphataemia in
3.0%. Risk factor analysis found associations between low
GFR and nephrectomywith or without nephrotoxic chemother-
apy (cisplatin, carboplatin, ifosfamide) and/or radiotherapy,
higher cumulative ifosfamide doses and high-dose cyclophos-
phamide (≥1 g/m2/course). In addition, hypomagnesaemia was
associated with cisplatin dose and/or nephrectomy, albuminuria
with ifosfamide dose and hypertension with abdominal radio-
therapy. Surprisingly, no predictors of hypophosphataemia
were identified, although this was measured in only 46% of
at-risk patients [53].
A small number of studies examined long-term renal tox-
icity of specific chemotherapy agents. A multicentre cross-
sectional study of 183 children and adolescents previously
treated with a median ifosfamide dose of 54 g/m2 at median
age of 9.3 (0.4–27.2) years and studied once at a follow-up of
10 (5–20.7) years, found a reduced GFR (<90ml/min/1.73m2)
in 21% related to older age at treatment and longer duration of
follow-up. Tmp/GFR was reduced in 24%, but only 1% were
hypophosphataemic. Increased tubular phosphate loss was re-
lated to higher cumulative ifosfamide dose (p = 0.02) and
longer duration of follow-up (p = 0.0005); of these factors,
ifosfamide dose had the larger effect on Tmp/GFR. Proteinuria
was observed in 12% [35].
Two smaller studies provided longitudinal data to evaluate
changes in renal function over prolonged follow-up after po-
tentially nephrotoxic chemotherapy. Both studied children and
adolescents at the end of treatment and 1 and 10 years later.
The first study evaluated 27 patients given a median cisplatin
dose of 500 mg/m2 and revealed marked interindividual var-
iability over the 10 years of follow-up. However, there was no
significant change in frequency of reduced GFR (<90 ml/min/
1.73m2) and hypomagnesaemia over the follow-up period.
Lower GFR at 10 years was related to older age at treatment
[41]. The second study assessed 25 patients given a median of
106 g/m2 ifosfamide, again showing considerable interindi-
vidual variability. However, more patients had a low GFR at
1 (72%) and 10 years (50%) years than at the end of treatment
(26%) (p = 0.006). In contrast, clinically significant tubular
toxicity present at the end of treatment resolved in all patients
10 years later. Neither dose nor age at treatment influenced the
outcomes at 10 years [15].
In conclusion, chronic nephrotoxicity persists and may in-
deed deteriorate in many CCS, although partial or complete
recovery are also well documented. Nevertheless, the occur-
rence of chronic glomerular dysfunction, proteinuria and hy-
pertension is worrying in view of their potential impact on
long-term health. The variable outcomes for tubular dysfunc-
tion are intriguing, with improvement usually seen after
ifosfamide in contrast to persistence in many survivors who
received cisplatin.
What do we think we know?
Guidelines and recommendations
Surveillance for late adverse effects is an increasingly impor-
tant part of long-term follow-up of CCS and has been in-
formed by the publication of long-term follow-up clinical
practice guidelines by several national organisations. The
International Late Effects of Childhood Cancer Guideline
Harmonisation Group (IGHG) is using a rigorous evidence-
based methodology to develop harmonised guidelines for sur-
veillance to facilitate early detection of late effects [54], and
renal toxicity is recognised as a high-priority topic. Whilst not
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yet available, it is anticipated that harmonised nephrotoxicity
surveillance guidelines will be completed within the next few
years.
The Dutch (LATER), UK (UKCCSG) and US (COG)
guidelines [55–57] agree that high-risk patients may be de-
fined as those who received ifosfamide, platinum drugs, renal
radiotherapy including total body irradiation (TBI) or ne-
phrectomy, but they are not as clear about the importance of
particular chemotherapy-conditioning regimens for
haemopoietic stem cell transplant as risk factors. They all
recommend surveillance for both glomerular and tubular im-
pairment, including measurement of serum creatinine, electro-
lytes, magnesium (if the patient received a platinum drug),
phosphate and bicarbonate (for recipients of ifosfamide), as
well as more general measures, including urinalysis (for pro-
teinuria) and blood pressure measurement.
However, the efficacy of surveillance following these rec-
ommendations is unproven. A recent study reported 370 CCS
who had undergone at least one annual long-term follow-up
evaluation (total 1188). Survivors of the full range of child-
hood malignancies were included, with a median age of
23.9 years at first evaluation and median follow-up from ma-
lignancy diagnosis of 10.5 years. The calculated yield of pos-
itive results (percentage of positives in at-risk previously un-
diagnosed patients) was disappointing, being <1% for glomer-
ular surveillance tests (urinalysis and urea/creatinine) and only
2.4% for renal tubular tests (at least two out of hypokalaemia,
hypomagnesaemia and hypophosphataemia) [58]. This low
yield may reflect a low rate of significant chronic nephrotox-
icity in the study population but it also highlights the paucity
of evidence regarding the best surveillance tests and thresh-
olds for nephrotoxicity in CCS. Furthermore, the implications
of detection or nondetection of positive results remains un-
clear. Although the IGHG renal surveillance guidelines, when
available, will hopefully clarify some of these uncertainties,
these findings illustrate the difficulties of designing effective
surveillance strategies that will detect potentially treatable late
effects in a timely manner capable of improving health
outcomes.
Pathogenesis
Ifosfamide nephrotoxicity is assumed to be caused by a toxic
metabolite produced in significant amounts in the kidney by
the breakdown of ifosfamide but not that of cyclophospha-
mide. Animal models of renal tubular cell culture suggest that
the mechanism involves cellular oxidative stress leading to
mitochondrial damage and energy depletion [59].
Chloroacetaldehyde has been implicated as a potential candi-
date, with the hypothesis that quantitative differences in its
production may account for the great variability in renal out-
comes in patients exposed to ifosfamide; some individuals
experience considerable toxicity with relatively small
cumulative doses, others appear to experience no adverse ef-
fects despite large doses [60]. However, chloroacetaldehyde is
not yet proven conclusively to be primarily or solely respon-
sible for ifosfamide nephrotoxicity, and uncertainty remains
about the cellular and molecular mechanisms of damage.
The identity of the agent responsible for platinum nephro-
toxicity is even less clear. The differential nephrotoxicity of
cisplatin and carboplatin affords a clue by suggesting that the
greater frequency and severity of toxicity after cisplatin results
from formation of increased amounts of a putative nephrotox-
ic metabolite due to increased lability of the chloride ligand of
cisplatin compared with the cyclobutene dicarboxylate group
of carboplatin. Many mechanisms of platinum nephrotoxicity
have been postulated, including direct cellular toxic, vasocon-
strictive and proinflammatory effects [61]. Several protective
agents have been suggested or investigated corresponding to
these mechanisms, most often in animal models or small clin-
ical pilot studies [62]. Amifostine is an organic thiophosphate
prodrug hydrolysed in vivo by alkaline phosphatase to an
active cytoprotectant thiol compound, WR-1065, which pro-
tects healthy cells preferentially to malignant cells. It reduced
nephrotoxicity in a randomised clinical trial in women receiv-
ing cisplatin for ovarian cancer [63], and American Society of
Clinical Oncology (ASCO) guidelines recommend its use be
considered in patients receiving cisplatin [64]. However, no
protective agents have yet demonstrated convincing benefit in
children, and none has entered routine clinical practice in pae-
diatric malignancies.
Uncertainty about the primary pathogenesis of ifosfamide-
and platinum-induced nephrotoxicity is particularly relevant
since tubular injury is a prominent component in both, and
very important in light of the increasing recognition that prox-
imal tubular injury is an important driver of subsequent pro-
gressive CKD [65, 66].
What are we still learning?
How common is very-long-term nephrotoxicity
and what are its implications?
There are many aspects of nephrotoxicity about which much
remains to be learned. It is important to recognise that vigi-
lance is required, since the nephrotoxicity of ifosfamide was
not predicted by preclinical studies, and since apparently nor-
mal renal function on completion of treatment does not nec-
essarily exclude the later development of significant nephro-
toxicity. Indeed, chronic renal impairment may not become
evident until months or years later, as shown by the often
delayed onset of nitrosourea nephrotoxicity [67], highlighting
the importance of long-term follow-up studies.
Despite clinical experience of long-term renal toxicity in a
small number of individual children due to other treatments,
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such as high-dose methotrexate, renal radiotherapy and sur-
gery—and, in the case of nephrectomy, confirmation of its
importance in causing CKD (stage ≥2) in a large cohort study
[52]—there is much less published information about the clin-
ical nature and long-term outcome of nephrotoxicity due to
these treatments. Indeed, large cohort studies have failed to
demonstrate a significant association between high-dose meth-
otrexate and chronic nephrotoxicity in CCS [52, 68]. Similarly,
notwithstanding the recent evidence about outcomes 5–20 years
after treatment, there is still very little published information
about the prevalence and nature of nephrotoxicity at later time
points. This is particularly important given the expected decline
in renal function that occurs as part of the natural ageing pro-
cess and the recent observation that many CCS display evi-
dence of an accelerated ageing phenotype manifest by frailty
[69]. It is likely that the reduction of physiological reserve
implied by this process will include renal function and will
interact adversely with co-existent chronic nephrotoxicity, po-
tentially leading to an increased risk of clinically significant
renal impairment in middle-aged and older survivors.
There is increasing recognition of the acute nephrotoxicity
of new, targeted, anticancer drugs, which is derived predomi-
nantly from adult studies [70]; however, insufficient data and
follow-up duration is available to evaluate long-term outcomes.
Recent data has highlighted the occurrence of AKI with histo-
logical features of acute tubulointerstitial nephritis in up to 2%
of adults treated with immune checkpoint inhibitors, although
corticosteroids led to partial improvement in most patients [71,
72]. There is also increasing recognition of minimal change/
focal segmental glomerulosclerosis and TMA in patients treat-
ed with vascular endothelial growth factor (VEGF) inhibitors
[73]. Again, these glomerular disorders appear to be reversible
with discontinuation of the causative agents. Nevertheless, in
view of the risk of significant renal damage, which may have
potentially severe and lasting consequences, active surveillance
has been recommended in patients treated with immune check-
point inhibitors [74]. In a broader sense, the emerging field of
onconephrology reflects the importance of studying adverse
renal outcomes in patients treated with new anticancer agents
to increase our understanding of the causes and natural history
of AKI and CKD in the growing population of cancer survivors
of all ages, as well as providing information for individual
patient management [73–75].
Can we predict or prevent chronic nephrotoxicity?
Accurate prediction of the likelihood and severity of renal
toxicity after treatment with known nephrotoxic agents is not
yet feasible despite considerable study of potential risk fac-
tors. Further research is required to examine other potential
confounding and causative factors, including host factors such
as genetic polymorphisms, baseline renal function and
treatment-related pharmacokinetic variables.
Treatment-induced nephrotoxicity may be prevented or re-
duced by general or specific strategies. General approaches to
the use of potentially nephrotoxic agents, based on our admitted-
ly incomplete knowledge of risk factors, may include carefully
considered treatment adjustments, such as dose limitation where
the increased toxicity of higher doses is clear (e.g. for ifosfamide
and radiotherapy) [3, 12], or subtotal rather than total nephrec-
tomy (nephron-sparing surgery) [76]. For drug-induced nephro-
toxicity, hyperhydration is used with most cisplatin, ifosfamide
andmethotrexate regimens to reduce renal accumulation of toxic
metabolites, whilst some cisplatin administration schedules also
employ mannitol diuresis, although there is little clear evidence
that this reduces nephrotoxicity [77].
Ideally, nephrotoxicity will be reduced or—hopefully—
eliminated by the development of nontoxic or less toxic
agents, but this is likely to require improved understanding
of the detailed pathogenesis of renal damage.
Key summary points
1. Nephrotoxicity is an important long-term risk for CCS.
2. Many disease and treatment-related causes, including
ifosfamide, cisplatin, carboplatin, radiotherapy involving
the kidneys and nephrectomy, may contribute individual-
ly or collectively to renal toxicity.
3. Ifosfamide, cisplatin and carboplatin may all cause glo-
merular or renal tubular toxicity, or both, although the
clinical manifestations of tubulopathy differ between
ifosfamide (ranging from hypophosphataemia to a
Fanconi syndrome) and the platinum agents (typically
hypomagnesaemia).
4. Currently recognised risk factors do not predict all epi-
sodes of nephrotoxicity.
5. Improved understanding of the pathogenesis of nephro-
toxicity is vital to reduce the frequency and severity of
nephrotoxicity.
Multiple-choice questions (answers are provided following
the reference list)
1. Which of the following statements about chronic nephro-
toxicity is correct?
a. The most common adverse effect of nephrectomy is
tubular dysfunction.
b. Radiotherapy exposing the kidneys may cause hyper-
tension years after treatment.
c. Ifosfamide causes hypomagnesaemia.
d. The commonest manifestation of the tubular toxicity of
platinum drugs is the Fanconi syndrome.
e. Acute kidney injury usually leads to later tubular
toxicity.
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2. The most common presentation of chronic ifosfamide
nephrotoxicity in children is:
a. Acute kidney injury.
b. Hypomagnesaemia.
c. Hypophosphataemia.
d. Hypocalcaemia.
e. Haematuria.
3. Which of the following statements about prevention or
prediction of chronic nephrotoxicity is correct?
a. Mesna prevents cisplatin nephrotoxicity.
b. Children with ifosfamide-induced hypophosphataemia
should always be switched from ifosfamide to
cyclophosphamide.
c. Mannitol prevents ifosfamide nephrotoxicity.
d. The use of new drugs in which preclinical studies have
not demonstrated renal toxicity will eliminate the risk
of chronic nephrotoxicity.
e. Absence of renal toxicity at the end of anticancer treat-
ment does not exclude future chronic nephrotoxicity.
4. Platinum drug nephrotoxicity in children:
a. Is more common after carboplatin than after cisplatin
b. Recovers by 10 years after treatment
c. Randomised controlled trial evidence shows it can be
prevented by amifostine
d. Can lead to cardiac arrhythmias
e. Is commoner in infants than in older children
5. Which of the following statements about management of
chronic nephrotoxicity is correct?
a. Renal transplantation for ESRD is contraindicated in
CCS.
b. Magnesium supplements may be required to treat or pre-
vent complications of platinum drug nephrotoxicity.
c. Vitamin D should be avoided in children with
ifosfamide nephrotoxicity.
d. Hypertension is to be expected in patients with cisplat-
in nephrotoxicity and does not need to be treated.
e. GFR should be measured (not calculated) every year in
CCS.
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